Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

BACKGROUND: Therapeutic antibodies targeting EGFR have activity in advanced colorectal cancer, but results from clinical trials are inconsistent and the population in which most benefit is derived is uncertain. Our aim was to assess the addition of panitumumab to irinotecan in pretreated advanced co...

Descripción completa

Detalles Bibliográficos
Autores principales: Seymour, Matthew T, Brown, Sarah R, Middleton, Gary, Maughan, Timothy, Richman, Susan, Gwyther, Stephen, Lowe, Catherine, Seligmann, Jennifer F, Wadsley, Jonathan, Maisey, Nick, Chau, Ian, Hill, Mark, Dawson, Lesley, Falk, Stephen, O'Callaghan, Ann, Benstead, Kim, Chambers, Philip, Oliver, Alfred, Marshall, Helen, Napp, Vicky, Quirke, Phil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699713/
https://www.ncbi.nlm.nih.gov/pubmed/23725851
http://dx.doi.org/10.1016/S1470-2045(13)70163-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699713/
https://www.ncbi.nlm.nih.gov/pubmed/23725851
http://dx.doi.org/10.1016/S1470-2045(13)70163-3

Ejemplares similares